StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs on Bristol-Myers Squibb Co. (BMY): 'Complicated Setup for Upcoming Admilparant Phase 3 IPF Readout'
September 23, 2026 6:54 AM
Goldman Sachs analyst Asad Haider reiterated a Neutral rating and $63.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
